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OBJECTIVES: To model the long-term metabolic costs and con-
sequences of antipsychotic therapy for chronic schizophrenia.
METHODS: We developed a Markov model to simulate long-
term treatment courses of 10,000 chronic schizophrenia patients
using annual cycles over a 10-year period. The model was devel-
oped with psychiatrists, an endocrinologist, and a cardiologist
and simulated individual patients. Patient health status (comor-
bidities, lipid levels, body mass index, and blood pressure) could
change as a function of treatment-related events. Probabilities
were determined from published pooled analyses of clinical trial
data. Costs and resource utilization patterns were obtained from
published data and standard costing sources. The model esti-
mated costs of long-term consequences of weight gain, such as
diabetes and coronary heart disease. We used data from the
Framingham Heart Study and Nurses’ Health study to assess
risks for weight gain–induced diabetes and cardiovascular
events. Outcomes included total number of patients with meta-
bolic events and associated costs. RESULTS: Fewer patients
treated with ziprasidone developed diabetes compared with
other atypical antipsychotics. The greatest difference was
observed between ziprasidone and olanzapine: costs for the
entire cohort were $12.3 million vs $32.9 million for ziprasidone
vs olanzapine, respectively. Increased diabetes risk and lipid
levels translated into higher risk for CHD. At 10 years, an addi-
tional 235 olanzapine-treated patients developed CHD vs
ziprasidone. Costs were again lowest for ziprasidone compared
with other atypical antipsychotics. CONCLUSIONS: Adverse
events common to some atypical antipsychotics (ie, weight gain)
can have a deleterious long-term metabolic impact and should
be considered when prescribing an agent for the treatment of
schizophrenia.
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OBJECTIVES: To perform an economic evaluation of Puregon
Pen and the conventional syringe system with menotropin in the
treatment of IVF/ICSI by comparing the process-utilities and the
costs for the current Dutch situation. METHODS: A conjoint
analysis (CA) was performed to express the preference of women
for the different administration forms of FSH as process-utilities
ranging from 0 to 1. In the CA, women were asked to give their
preference for the different administration forms that were
described by the levels of ﬁve attributes. A decision analytic
model was developed to estimate the costs of an average IVF
cycle in The Netherlands from the societal perspective. Epi-
demiologic and costing data were drawn from the available 
literature or were provided by experts. RESULTS: The process-
utility was estimated to be 2.6 (p < 0.05) higher for Puregon Pen
compared to the conventional syringe containing menotropin.
On a scale from 0 to 1, the process-utility was 0.96 (CI between
0.94 and 0.97) for Puregon Pen and 0.36 (CI: 0.30–0.46) for the
conventional syringe, resulting in an incremental process-utility
between 0.57 and 0.61. The additional costs per cycle for this
increase are estimated to be €60–194. CONCLUSIONS: Com-
pared with the conventional menotropin administration form,
the added value of Puregon Pen was 2.6 times higher at an extra
cost per cycle of €60–194. The comparison shows that the utility-
gain is substantial and that the additional costs are minimal.
Therefore, it can be concluded that Puregon Pen is a cost-effec-
tive administration form.
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OBJECTIVES: Unplanned pregnancy can have a signiﬁcant
impact on the individuals involved. With around one-third of
pregnancies being unplanned, it is a signiﬁcant problem for
health care systems and society. The objective of this analysis was
to estimate the cost of unintended pregnancy from a UK
National Health Service perspective using a decision-analytic
modelling approach. METHODS: The cost of unintended preg-
nancy was evaluated using a decision-analytic Markov model. A
review of medical literature and government statistics was under-
taken to identify probabilities of alternative pregnancy out-
comes. The model was then used to predict the likelihood of
these outcomes: ectopic pregnancy; spontaneous abortion;
induced abortion; vaginal delivery; C-section; full term/pre-term
delivery. Costs were derived from NHS reference costs and the
literature and inﬂated to 2002 prices. Post-natal costs were
excluded. To obtain a stable estimate of costs, we simulated a
cohort of 100,000 women using oral contraceptives (OC’s) over
a 2-year period. RESULTS: The model predicts that in this
cohort of 100,000 OC users there would be 14,211 pregnancies
over two years (approximately 7% per annum). The most
common outcomes were vaginal delivery (53%), elective abor-
tion (26%) and C-section (12%). The annual cost of these events
was 10.3 million pounds (GBP), with an average event cost of
1460GBP, varying from 2448GBP for C-sections to 452GBP for
spontaneous abortions. Assuming that 30% of the 764,000 con-
ceptions that occurred in 2001 were unplanned, this would
equate to a total annual cost of 335 million GBP in the UK.
CONCLUSIONS: Unintended pregnancy places a large ﬁnancial
burden on the NHS. Investment in interventions that reduce
unintended pregnancy rates are needed.
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OBJECTIVES: Analyze the incremental cost that would be
incurred if the WHO Mother-Baby Package standards were
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applied in a rural district in Mexico. Identify barriers to be con-
sidered in its implementation. METHODS: Cost Study: A pilot
cross-sectional, multicenter case study was conducted in 2001 in
Sanitary District No. III, State of Morelos, Mexico. A general
hospital, an urban health centre and two rural health centres, all
managed by the Ministry of Health, were selected. The Mother-
Baby Package Costing Spreadsheet was used to estimate the total
cost and cost by intervention under the current model and
Mother-Baby Package model. Qualitative Study: Key informants
from the hospital, the urban centre and eight rural health centres
were interviewed. The “3 Delays Model” was used to identify
barriers to be considered. RESULTS: The total cost of the
Mother-Baby Package is twice the cost of the current child and
maternal health care model in Morelos, Mexico. Of the 18 inter-
ventions evaluated, those consuming the highest proportion of
total costs were antenatal-care and normal-delivery. Personnel
costs represent more than half of total costs. Barriers identiﬁed
were machismo, culture and the negative perception of health
centres amongst users (causing delay in deciding to seek care),
difﬁculty obtaining transportation in emergency situations (gen-
erating delay in reaching a ﬁrst referral level facility); and short-
age of drugs, adequate equipment and trained staff (causing
delay in receiving care after arriving at the facility). CONCLU-
SIONS: Improving the delivery of child and maternal health care
in a poor setting in accordance with the Mother-Baby Package
standards would require a budget two times that which is cur-
rently assigned to these services. However, before implementing
a scaled-up version of the package it would be essential to
manage problems that appear to be barriers that exist in pro-
viding and accessing appropriate maternal and child health care.
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OBJECTIVES: To assess the clinimetric properties of the Spanish
version of the Self-Esteem And Relationship (SEAR) question-
naire to be used in Spain with patients with ED. METHODS:
The SEAR questionnaire comprises 14 items divided into two
domains: Sexual Relationship (8 items) and Conﬁdence (6 items),
the latter comprising Self-Esteem (4 items) and Overall Rela-
tionship (2 items). The USA-English-version of SEAR question-
naire was adapted linguistically into Spanish by using forward
and back translation methods and a conceptual equivalence
approach. The SEAR questionnaire was administered to a group
of patients with ED (IIEF < 26) seven days before starting treat-
ment and at baseline and after three months of treatment (group
A), and to a group of healthy control subjects (IIEF ≥ 26) (group
B) in a single visit. SF-12 and HAD scales were also adminis-
tered. RESULTS: Out of 831 recruited subjects (n = 732, group
A; n = 99, group B), 559 subjects were included as evaluable for
validation analysis (n = 504, group A; n = 55, group B). The per-
centage of patients without response was < 5% for all domains.
Cronbach’s Alpha coefﬁcient was 0.92 and 0.86 in groups A and
B. The SEAR questionnaire discriminated between patients and
controls (area under curve = 0.999) and groups of patients by
severity of ED (Kruskall-Wallis test: p < 0.0001). Correlation was
high with Erectile Function scale of IIEF (r = 0.69) and moder-
ate with HAD (r = -0.41) and SF-12 Mental Health (r = 0.38).
The SEAR questionnaire also showed responsiveness with
improvement in scores from start to end of treatment (Mann-
Whitney-Wilcoxon test: p < 0.0001). CONCLUSIONS: The
SEAR questionnaire showed adequate feasibility, reliability,
validity and responsiveness for its use for measuring the emo-
tional tension and relationship difﬁculties associated with erec-
tile dysfunction.
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OBJECTIVES: Assisted Reproduction is among the fastest
growing areas of medicine, rising debates about ﬁnancing in vitro
fertilisation (IVF) or other assisted reproductive techniques by
national third party payer. This study describes policies of infer-
tility treatment as well as willingness to pay for treatment in
affected couples in Germany (contribution-ﬁnanced health care
system) and the U.K. (tax-ﬁnanced health care system).
METHODS: Literature review with the key words: infertility,
willingness to pay, epidemiology. For assessment of national
reimbursement policies, websites of the respective health care
institutions were reviewed. RESULTS: In 2001, over 25,000 IVF
treatment cycles were carried out in Great Britain, 25% being
funded by the National Health Service. New clinical guidelines
accepted by the Department of Health, assure that from 2005,
more assisted reproduction services are covered by the NHS,
such as one full cycle of IVF. Over 2/3 of the patients currently
paying privately are expected to demand for NHS services result-
ing in an enormous increase in IVF treatment. In Germany, about
75,000 treatments were performed in 2001. Since January 2004,
German statutory sick funds restricted reimbursement to 50%
of the costs for the ﬁrst three IVF treatment cycles. Due to these
regulations, changes in treatment patterns for IVF can be
expected for the future. An ongoing online-questioning revealed
that for only 60%, the decision for IVF treatment remained
unchanged, whereas the rest either postponed the decision or
cancelled IVF. Two studies (USA, Sweden) revealed the willing-
ness to pay of infertile couples to be 14,500€ or more. CON-
CLUSIONS: Contradictory dynamics between willingness to pay
and change of mind due to restrictive reimbursement policies
show need for more research in the ﬁeld of infertility treatment.
Economic and social consequences of changing frame conditions
for IVF should be closely assessed, to ensure high quality of life
for affected couples.
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OBJECTIVES: Adaptation and validation of measures of short-
term and long-term consequences of false positive screening-
mammography. METHODS: After translation (including quality
